ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global 23-valent Pneumococcal Vaccine Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-0P12515
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global 7 Valent Pneumococcal Vaccine Industry Research Report Growth Trends and Competitive Analysis 2022 2028
BUY CHAPTERS

Global 23-valent Pneumococcal Vaccine Market Research Report 2025

Code: QYRE-Auto-0P12515
Report
July 2025
Pages:81
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Merck
Sanofipasteur
CDIBP
Kexing Bio
Changsheng Bio-Technology
Huaan Science and Technology Innovation

23-valent Pneumococcal Vaccine Market Size

The global market for 23-valent Pneumococcal Vaccine was valued at US$ 1556 million in the year 2024 and is projected to reach a revised size of US$ 2095 million by 2031, growing at a CAGR of 4.4% during the forecast period.

23-valent Pneumococcal Vaccine Market

23-valent Pneumococcal Vaccine Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for 23-valent Pneumococcal Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding 23-valent Pneumococcal Vaccine.
The 23-valent Pneumococcal Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global 23-valent Pneumococcal Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the 23-valent Pneumococcal Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of 23-valent Pneumococcal Vaccine Market Report

Report Metric Details
Report Name 23-valent Pneumococcal Vaccine Market
Accounted market size in year US$ 1556 million
Forecasted market size in 2031 US$ 2095 million
CAGR 4.4%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Merck, Sanofipasteur, CDIBP, Kexing Bio, Changsheng Bio-Technology, Huaan Science and Technology Innovation
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of 23-valent Pneumococcal Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of 23-valent Pneumococcal Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is 23-valent Pneumococcal Vaccine Market growing?

Ans: The 23-valent Pneumococcal Vaccine Market witnessing a CAGR of 4.4% during the forecast period 2025-2031.

What is the 23-valent Pneumococcal Vaccine Market size in 2031?

Ans: The 23-valent Pneumococcal Vaccine Market size in 2031 will be US$ 2095 million.

Who are the main players in the 23-valent Pneumococcal Vaccine Market report?

Ans: The main players in the 23-valent Pneumococcal Vaccine Market are Merck, Sanofipasteur, CDIBP, Kexing Bio, Changsheng Bio-Technology, Huaan Science and Technology Innovation

What are the Application segmentation covered in the 23-valent Pneumococcal Vaccine Market report?

Ans: The Applications covered in the 23-valent Pneumococcal Vaccine Market report are Chronic Cardiovascular Disease, Chronic Lung Disease, Chronic Liver Disease, People Living with Hiv, Leukemia, Lymphoma, Multiple Myeloma, General Malignancy, Chronic Kidney Disease, Other

What are the Type segmentation covered in the 23-valent Pneumococcal Vaccine Market report?

Ans: The Types covered in the 23-valent Pneumococcal Vaccine Market report are Single Dose Vial, Pre-filled Syringe

Recommended Reports

Pneumococcal & Meningitis Vaccines

COVID & Influenza Vaccines

Vaccine Packaging & Devices

1 23-valent Pneumococcal Vaccine Market Overview
1.1 Product Definition
1.2 23-valent Pneumococcal Vaccine by Type
1.2.1 Global 23-valent Pneumococcal Vaccine Market Value Comparison by Type (2024 VS 2031)
1.2.2 Single Dose Vial
1.2.3 Pre-filled Syringe
1.3 23-valent Pneumococcal Vaccine by Application
1.3.1 Global 23-valent Pneumococcal Vaccine Market Value by Application (2024 VS 2031)
1.3.2 Chronic Cardiovascular Disease
1.3.3 Chronic Lung Disease
1.3.4 Chronic Liver Disease
1.3.5 People Living with Hiv
1.3.6 Leukemia
1.3.7 Lymphoma
1.3.8 Multiple Myeloma
1.3.9 General Malignancy
1.3.10 Chronic Kidney Disease
1.4 Global 23-valent Pneumococcal Vaccine Market Size Estimates and Forecasts
1.4.1 Global 23-valent Pneumococcal Vaccine Revenue 2020-2031
1.4.2 Global 23-valent Pneumococcal Vaccine Sales 2020-2031
1.4.3 Global 23-valent Pneumococcal Vaccine Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 23-valent Pneumococcal Vaccine Market Competition by Manufacturers
2.1 Global 23-valent Pneumococcal Vaccine Sales Market Share by Manufacturers (2020-2025)
2.2 Global 23-valent Pneumococcal Vaccine Revenue Market Share by Manufacturers (2020-2025)
2.3 Global 23-valent Pneumococcal Vaccine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of 23-valent Pneumococcal Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of 23-valent Pneumococcal Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of 23-valent Pneumococcal Vaccine, Product Type & Application
2.7 Global Key Manufacturers of 23-valent Pneumococcal Vaccine, Date of Enter into This Industry
2.8 Global 23-valent Pneumococcal Vaccine Market Competitive Situation and Trends
2.8.1 Global 23-valent Pneumococcal Vaccine Market Concentration Rate
2.8.2 The Global 5 and 10 Largest 23-valent Pneumococcal Vaccine Players Market Share by Revenue
2.8.3 Global 23-valent Pneumococcal Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global 23-valent Pneumococcal Vaccine Market Scenario by Region
3.1 Global 23-valent Pneumococcal Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global 23-valent Pneumococcal Vaccine Sales by Region: 2020-2031
3.2.1 Global 23-valent Pneumococcal Vaccine Sales by Region: 2020-2025
3.2.2 Global 23-valent Pneumococcal Vaccine Sales by Region: 2026-2031
3.3 Global 23-valent Pneumococcal Vaccine Revenue by Region: 2020-2031
3.3.1 Global 23-valent Pneumococcal Vaccine Revenue by Region: 2020-2025
3.3.2 Global 23-valent Pneumococcal Vaccine Revenue by Region: 2026-2031
3.4 North America 23-valent Pneumococcal Vaccine Market Facts & Figures by Country
3.4.1 North America 23-valent Pneumococcal Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America 23-valent Pneumococcal Vaccine Sales by Country (2020-2031)
3.4.3 North America 23-valent Pneumococcal Vaccine Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe 23-valent Pneumococcal Vaccine Market Facts & Figures by Country
3.5.1 Europe 23-valent Pneumococcal Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe 23-valent Pneumococcal Vaccine Sales by Country (2020-2031)
3.5.3 Europe 23-valent Pneumococcal Vaccine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific 23-valent Pneumococcal Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific 23-valent Pneumococcal Vaccine Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific 23-valent Pneumococcal Vaccine Sales by Region (2020-2031)
3.6.3 Asia Pacific 23-valent Pneumococcal Vaccine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America 23-valent Pneumococcal Vaccine Market Facts & Figures by Country
3.7.1 Latin America 23-valent Pneumococcal Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America 23-valent Pneumococcal Vaccine Sales by Country (2020-2031)
3.7.3 Latin America 23-valent Pneumococcal Vaccine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa 23-valent Pneumococcal Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa 23-valent Pneumococcal Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa 23-valent Pneumococcal Vaccine Sales by Country (2020-2031)
3.8.3 Middle East and Africa 23-valent Pneumococcal Vaccine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global 23-valent Pneumococcal Vaccine Sales by Type (2020-2031)
4.1.1 Global 23-valent Pneumococcal Vaccine Sales by Type (2020-2025)
4.1.2 Global 23-valent Pneumococcal Vaccine Sales by Type (2026-2031)
4.1.3 Global 23-valent Pneumococcal Vaccine Sales Market Share by Type (2020-2031)
4.2 Global 23-valent Pneumococcal Vaccine Revenue by Type (2020-2031)
4.2.1 Global 23-valent Pneumococcal Vaccine Revenue by Type (2020-2025)
4.2.2 Global 23-valent Pneumococcal Vaccine Revenue by Type (2026-2031)
4.2.3 Global 23-valent Pneumococcal Vaccine Revenue Market Share by Type (2020-2031)
4.3 Global 23-valent Pneumococcal Vaccine Price by Type (2020-2031)
5 Segment by Application
5.1 Global 23-valent Pneumococcal Vaccine Sales by Application (2020-2031)
5.1.1 Global 23-valent Pneumococcal Vaccine Sales by Application (2020-2025)
5.1.2 Global 23-valent Pneumococcal Vaccine Sales by Application (2026-2031)
5.1.3 Global 23-valent Pneumococcal Vaccine Sales Market Share by Application (2020-2031)
5.2 Global 23-valent Pneumococcal Vaccine Revenue by Application (2020-2031)
5.2.1 Global 23-valent Pneumococcal Vaccine Revenue by Application (2020-2025)
5.2.2 Global 23-valent Pneumococcal Vaccine Revenue by Application (2026-2031)
5.2.3 Global 23-valent Pneumococcal Vaccine Revenue Market Share by Application (2020-2031)
5.3 Global 23-valent Pneumococcal Vaccine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Company Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck 23-valent Pneumococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Merck 23-valent Pneumococcal Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Sanofipasteur
6.2.1 Sanofipasteur Company Information
6.2.2 Sanofipasteur Description and Business Overview
6.2.3 Sanofipasteur 23-valent Pneumococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Sanofipasteur 23-valent Pneumococcal Vaccine Product Portfolio
6.2.5 Sanofipasteur Recent Developments/Updates
6.3 CDIBP
6.3.1 CDIBP Company Information
6.3.2 CDIBP Description and Business Overview
6.3.3 CDIBP 23-valent Pneumococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 CDIBP 23-valent Pneumococcal Vaccine Product Portfolio
6.3.5 CDIBP Recent Developments/Updates
6.4 Kexing Bio
6.4.1 Kexing Bio Company Information
6.4.2 Kexing Bio Description and Business Overview
6.4.3 Kexing Bio 23-valent Pneumococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Kexing Bio 23-valent Pneumococcal Vaccine Product Portfolio
6.4.5 Kexing Bio Recent Developments/Updates
6.5 Changsheng Bio-Technology
6.5.1 Changsheng Bio-Technology Company Information
6.5.2 Changsheng Bio-Technology Description and Business Overview
6.5.3 Changsheng Bio-Technology 23-valent Pneumococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Changsheng Bio-Technology 23-valent Pneumococcal Vaccine Product Portfolio
6.5.5 Changsheng Bio-Technology Recent Developments/Updates
6.6 Huaan Science and Technology Innovation
6.6.1 Huaan Science and Technology Innovation Company Information
6.6.2 Huaan Science and Technology Innovation Description and Business Overview
6.6.3 Huaan Science and Technology Innovation 23-valent Pneumococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Huaan Science and Technology Innovation 23-valent Pneumococcal Vaccine Product Portfolio
6.6.5 Huaan Science and Technology Innovation Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 23-valent Pneumococcal Vaccine Industry Chain Analysis
7.2 23-valent Pneumococcal Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 23-valent Pneumococcal Vaccine Production Mode & Process Analysis
7.4 23-valent Pneumococcal Vaccine Sales and Marketing
7.4.1 23-valent Pneumococcal Vaccine Sales Channels
7.4.2 23-valent Pneumococcal Vaccine Distributors
7.5 23-valent Pneumococcal Vaccine Customer Analysis
8 23-valent Pneumococcal Vaccine Market Dynamics
8.1 23-valent Pneumococcal Vaccine Industry Trends
8.2 23-valent Pneumococcal Vaccine Market Drivers
8.3 23-valent Pneumococcal Vaccine Market Challenges
8.4 23-valent Pneumococcal Vaccine Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Merck
Sanofipasteur
CDIBP
Kexing Bio
Changsheng Bio-Technology
Huaan Science and Technology Innovation
List of Tables
 Table 1. Global 23-valent Pneumococcal Vaccine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global 23-valent Pneumococcal Vaccine Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global 23-valent Pneumococcal Vaccine Market Competitive Situation by Manufacturers in 2024
 Table 4. Global 23-valent Pneumococcal Vaccine Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global 23-valent Pneumococcal Vaccine Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global 23-valent Pneumococcal Vaccine Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global 23-valent Pneumococcal Vaccine Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market 23-valent Pneumococcal Vaccine Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of 23-valent Pneumococcal Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of 23-valent Pneumococcal Vaccine, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of 23-valent Pneumococcal Vaccine, Product Type & Application
 Table 12. Global Key Manufacturers of 23-valent Pneumococcal Vaccine, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global 23-valent Pneumococcal Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in 23-valent Pneumococcal Vaccine as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global 23-valent Pneumococcal Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global 23-valent Pneumococcal Vaccine Sales by Region (2020-2025) & (K Units)
 Table 18. Global 23-valent Pneumococcal Vaccine Sales Market Share by Region (2020-2025)
 Table 19. Global 23-valent Pneumococcal Vaccine Sales by Region (2026-2031) & (K Units)
 Table 20. Global 23-valent Pneumococcal Vaccine Sales Market Share by Region (2026-2031)
 Table 21. Global 23-valent Pneumococcal Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Region (2020-2025)
 Table 23. Global 23-valent Pneumococcal Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Region (2026-2031)
 Table 25. North America 23-valent Pneumococcal Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America 23-valent Pneumococcal Vaccine Sales by Country (2020-2025) & (K Units)
 Table 27. North America 23-valent Pneumococcal Vaccine Sales by Country (2026-2031) & (K Units)
 Table 28. North America 23-valent Pneumococcal Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America 23-valent Pneumococcal Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe 23-valent Pneumococcal Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe 23-valent Pneumococcal Vaccine Sales by Country (2020-2025) & (K Units)
 Table 32. Europe 23-valent Pneumococcal Vaccine Sales by Country (2026-2031) & (K Units)
 Table 33. Europe 23-valent Pneumococcal Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe 23-valent Pneumococcal Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific 23-valent Pneumococcal Vaccine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific 23-valent Pneumococcal Vaccine Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific 23-valent Pneumococcal Vaccine Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific 23-valent Pneumococcal Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific 23-valent Pneumococcal Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America 23-valent Pneumococcal Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America 23-valent Pneumococcal Vaccine Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America 23-valent Pneumococcal Vaccine Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America 23-valent Pneumococcal Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America 23-valent Pneumococcal Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa 23-valent Pneumococcal Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa 23-valent Pneumococcal Vaccine Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa 23-valent Pneumococcal Vaccine Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa 23-valent Pneumococcal Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa 23-valent Pneumococcal Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global 23-valent Pneumococcal Vaccine Sales (K Units) by Type (2020-2025)
 Table 51. Global 23-valent Pneumococcal Vaccine Sales (K Units) by Type (2026-2031)
 Table 52. Global 23-valent Pneumococcal Vaccine Sales Market Share by Type (2020-2025)
 Table 53. Global 23-valent Pneumococcal Vaccine Sales Market Share by Type (2026-2031)
 Table 54. Global 23-valent Pneumococcal Vaccine Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global 23-valent Pneumococcal Vaccine Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Type (2020-2025)
 Table 57. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Type (2026-2031)
 Table 58. Global 23-valent Pneumococcal Vaccine Price (US$/Unit) by Type (2020-2025)
 Table 59. Global 23-valent Pneumococcal Vaccine Price (US$/Unit) by Type (2026-2031)
 Table 60. Global 23-valent Pneumococcal Vaccine Sales (K Units) by Application (2020-2025)
 Table 61. Global 23-valent Pneumococcal Vaccine Sales (K Units) by Application (2026-2031)
 Table 62. Global 23-valent Pneumococcal Vaccine Sales Market Share by Application (2020-2025)
 Table 63. Global 23-valent Pneumococcal Vaccine Sales Market Share by Application (2026-2031)
 Table 64. Global 23-valent Pneumococcal Vaccine Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global 23-valent Pneumococcal Vaccine Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Application (2020-2025)
 Table 67. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Application (2026-2031)
 Table 68. Global 23-valent Pneumococcal Vaccine Price (US$/Unit) by Application (2020-2025)
 Table 69. Global 23-valent Pneumococcal Vaccine Price (US$/Unit) by Application (2026-2031)
 Table 70. Merck Company Information
 Table 71. Merck Description and Business Overview
 Table 72. Merck 23-valent Pneumococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Merck 23-valent Pneumococcal Vaccine Product
 Table 74. Merck Recent Developments/Updates
 Table 75. Sanofipasteur Company Information
 Table 76. Sanofipasteur Description and Business Overview
 Table 77. Sanofipasteur 23-valent Pneumococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Sanofipasteur 23-valent Pneumococcal Vaccine Product
 Table 79. Sanofipasteur Recent Developments/Updates
 Table 80. CDIBP Company Information
 Table 81. CDIBP Description and Business Overview
 Table 82. CDIBP 23-valent Pneumococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. CDIBP 23-valent Pneumococcal Vaccine Product
 Table 84. CDIBP Recent Developments/Updates
 Table 85. Kexing Bio Company Information
 Table 86. Kexing Bio Description and Business Overview
 Table 87. Kexing Bio 23-valent Pneumococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Kexing Bio 23-valent Pneumococcal Vaccine Product
 Table 89. Kexing Bio Recent Developments/Updates
 Table 90. Changsheng Bio-Technology Company Information
 Table 91. Changsheng Bio-Technology Description and Business Overview
 Table 92. Changsheng Bio-Technology 23-valent Pneumococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Changsheng Bio-Technology 23-valent Pneumococcal Vaccine Product
 Table 94. Changsheng Bio-Technology Recent Developments/Updates
 Table 95. Huaan Science and Technology Innovation Company Information
 Table 96. Huaan Science and Technology Innovation Description and Business Overview
 Table 97. Huaan Science and Technology Innovation 23-valent Pneumococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Huaan Science and Technology Innovation 23-valent Pneumococcal Vaccine Product
 Table 99. Huaan Science and Technology Innovation Recent Developments/Updates
 Table 100. Key Raw Materials Lists
 Table 101. Raw Materials Key Suppliers Lists
 Table 102. 23-valent Pneumococcal Vaccine Distributors List
 Table 103. 23-valent Pneumococcal Vaccine Customers List
 Table 104. 23-valent Pneumococcal Vaccine Market Trends
 Table 105. 23-valent Pneumococcal Vaccine Market Drivers
 Table 106. 23-valent Pneumococcal Vaccine Market Challenges
 Table 107. 23-valent Pneumococcal Vaccine Market Restraints
 Table 108. Research Programs/Design for This Report
 Table 109. Key Data Information from Secondary Sources
 Table 110. Key Data Information from Primary Sources
 Table 111. Authors List of This Report


List of Figures
 Figure 1. Product Picture of 23-valent Pneumococcal Vaccine
 Figure 2. Global 23-valent Pneumococcal Vaccine Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global 23-valent Pneumococcal Vaccine Market Share by Type: 2024 & 2031
 Figure 4. Single Dose Vial Product Picture
 Figure 5. Pre-filled Syringe Product Picture
 Figure 6. Global 23-valent Pneumococcal Vaccine Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global 23-valent Pneumococcal Vaccine Market Share by Application: 2024 & 2031
 Figure 8. Chronic Cardiovascular Disease
 Figure 9. Chronic Lung Disease
 Figure 10. Chronic Liver Disease
 Figure 11. People Living with Hiv
 Figure 12. Leukemia
 Figure 13. Lymphoma
 Figure 14. Multiple Myeloma
 Figure 15. General Malignancy
 Figure 16. Chronic Kidney Disease
 Figure 17. Global 23-valent Pneumococcal Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 18. Global 23-valent Pneumococcal Vaccine Market Size (2020-2031) & (US$ Million)
 Figure 19. Global 23-valent Pneumococcal Vaccine Sales (2020-2031) & (K Units)
 Figure 20. Global 23-valent Pneumococcal Vaccine Average Price (US$/Unit) & (2020-2031)
 Figure 21. 23-valent Pneumococcal Vaccine Report Years Considered
 Figure 22. 23-valent Pneumococcal Vaccine Sales Share by Manufacturers in 2024
 Figure 23. Global 23-valent Pneumococcal Vaccine Revenue Share by Manufacturers in 2024
 Figure 24. Global 5 and 10 Largest 23-valent Pneumococcal Vaccine Players: Market Share by Revenue in 23-valent Pneumococcal Vaccine in 2024
 Figure 25. 23-valent Pneumococcal Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 26. Global 23-valent Pneumococcal Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 27. North America 23-valent Pneumococcal Vaccine Sales Market Share by Country (2020-2031)
 Figure 28. North America 23-valent Pneumococcal Vaccine Revenue Market Share by Country (2020-2031)
 Figure 29. United States 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Canada 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Europe 23-valent Pneumococcal Vaccine Sales Market Share by Country (2020-2031)
 Figure 32. Europe 23-valent Pneumococcal Vaccine Revenue Market Share by Country (2020-2031)
 Figure 33. Germany 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. France 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. U.K. 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Italy 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Russia 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Asia Pacific 23-valent Pneumococcal Vaccine Sales Market Share by Region (2020-2031)
 Figure 39. Asia Pacific 23-valent Pneumococcal Vaccine Revenue Market Share by Region (2020-2031)
 Figure 40. China 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Japan 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. South Korea 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. India 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Australia 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. China Taiwan 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Indonesia 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Thailand 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Malaysia 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Latin America 23-valent Pneumococcal Vaccine Sales Market Share by Country (2020-2031)
 Figure 50. Latin America 23-valent Pneumococcal Vaccine Revenue Market Share by Country (2020-2031)
 Figure 51. Mexico 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Brazil 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Argentina 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Middle East and Africa 23-valent Pneumococcal Vaccine Sales Market Share by Country (2020-2031)
 Figure 55. Middle East and Africa 23-valent Pneumococcal Vaccine Revenue Market Share by Country (2020-2031)
 Figure 56. Turkey 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. Saudi Arabia 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. UAE 23-valent Pneumococcal Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 59. Global Sales Market Share of 23-valent Pneumococcal Vaccine by Type (2020-2031)
 Figure 60. Global Revenue Market Share of 23-valent Pneumococcal Vaccine by Type (2020-2031)
 Figure 61. Global 23-valent Pneumococcal Vaccine Price (US$/Unit) by Type (2020-2031)
 Figure 62. Global Sales Market Share of 23-valent Pneumococcal Vaccine by Application (2020-2031)
 Figure 63. Global Revenue Market Share of 23-valent Pneumococcal Vaccine by Application (2020-2031)
 Figure 64. Global 23-valent Pneumococcal Vaccine Price (US$/Unit) by Application (2020-2031)
 Figure 65. 23-valent Pneumococcal Vaccine Value Chain
 Figure 66. Channels of Distribution (Direct Vs Distribution)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Pneumococcal Conjugate Vaccine PCV Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Streptococcus Pneumoniae Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Streptococcus Pneumoniae Polysaccharide Vaccine Market Research Report 2025
Paediatric Vaccine Market
Influenza A Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
13 Valent Pneumococcal Polysaccharide Conjugate Vaccine PCV13 Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Vaccines Delivery Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Vaccine Delivery Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Vaccine Digital Data Logger Market Insights Forecast to 2030
Pediatric Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global GP Vaccination Market Research Report 2025
mRNA Vaccines for Infectious Diseases Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Trivalent Flu Vaccine Market Insights Forecast to 2030
Global Therapeutic BCG Vaccines Market Insights Forecast to 2030
Global Attenuated Vaccine Market Research Report 2025
Vaccine Contract Manufacturing Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Livestock Vaccine Market Research Report 2025
Vaccine Ampoules Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Quadrivalent Flu Vaccine Market Insights Forecast to 2030
Respiratory Syncytial Virus Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions